Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hinova Pharma Completes $40 Million Series B for US-China Trials of Prostate Cancer Drug

publication date: Jul 29, 2019

Hinova Pharma, a Chengdu novel drug company, completed a $40 million Series B round led by Hermed Capital and Fosun Pharma. The company said it would use the proceeds to support its China-US Phase III trials of its treatment for metastatic castration-resistant prostate cancer (mCRPC), and a Phase I/II clinical study for a gout treatment. Founded in 2013, the company is developing a portfolio of eight novel drugs. The B round also included Lang Sheng Investment, Prosper Capital and other investors. More details....

Stock Symbols: (SHA: 600196; HK: 2196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.